Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $216.12 Average Price Target from Brokerages

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has been assigned an average rating of “Moderate Buy” from the eighteen analysts that are presently covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $216.12.

A number of research firms have recently commented on ALNY. BMO Capital Markets reissued an “outperform” rating and set a $234.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 27th. Wells Fargo & Company lowered their target price on Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating for the company in a report on Friday, February 16th. Needham & Company LLC reaffirmed a “buy” rating and issued a $200.00 target price on shares of Alnylam Pharmaceuticals in a report on Thursday, February 15th. Morgan Stanley lowered their target price on Alnylam Pharmaceuticals from $184.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, February 13th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $235.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 20th.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $153.56 on Friday. Alnylam Pharmaceuticals has a 52 week low of $143.52 and a 52 week high of $218.88. The stock has a market capitalization of $19.34 billion, a P/E ratio of -43.13 and a beta of 0.39. The stock has a fifty day moving average of $156.33 and a 200-day moving average of $168.46.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.10. The business had revenue of $439.72 million for the quarter, compared to analyst estimates of $439.38 million. During the same period last year, the firm posted ($1.68) EPS. Alnylam Pharmaceuticals’s quarterly revenue was up 31.2% on a year-over-year basis. On average, research analysts forecast that Alnylam Pharmaceuticals will post -4.61 earnings per share for the current year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Quent Capital LLC boosted its position in shares of Alnylam Pharmaceuticals by 246.0% during the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 123 shares in the last quarter. KB Financial Partners LLC bought a new position in Alnylam Pharmaceuticals in the first quarter worth approximately $35,000. Anchor Investment Management LLC bought a new position in Alnylam Pharmaceuticals in the fourth quarter worth approximately $38,000. Robeco Institutional Asset Management B.V. boosted its holdings in Alnylam Pharmaceuticals by 155.7% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 12,513 shares in the last quarter. Finally, GAMMA Investing LLC bought a new position in Alnylam Pharmaceuticals in the fourth quarter worth approximately $52,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.